Efficacy of XXXX monotherapy as the first-line treatment of metastatic @entity1722 -negative @entity0 .

@entity1 @entity172 @entity137 @entity0 @entity416 @entity5948 @entity3907 @entity1722
AIMS AND BACKGROUND: @entity416 is a potent and safe agent that can be used after @entity5948 and @entity3907 treatment in @entity1 with @entity0 ( @entity0 ). The purpose of this study was to investigate the efficacy and safety of @entity416 monotherapy as a first-line treatment in @entity1 epidermal receptor 2 ( @entity1722 )-negative @entity1 with @entity0 . METHODS AND STUDY DESIGN: In this single-center trial, a total of 109 @entity1722 -negative @entity1 with @entity0 who received @entity416 monotherapy as first-line treatment between 2003 and 2014 were retrospectively analyzed. Kaplan-Meier survival analysis was carried out for progression-free survival (PFS) and for overall survival (OS). Two-sided p values of <0.05 were considered statistically significant. RESULTS: Median PFS was 7.0    0.67 (confidence interval (CI) 5.6-8.3) months and median OS was 30    4.1 (CI 21.8-38.1) months. First-line @entity416 treatment for @entity1722 -negative @entity0 was more effective in the @entity172 receptor (ER)-positive @entity1 population compared to the ER-negative group (median PFS 9 vs 4 months (p = 0.002), median OS 33 vs 21 months (p = 0.01)). Indeed, the overall response rate in the ER-negative group was 16%, while this was calculated as 38% for ER-positive cases. While most of our @entity1 population was treated with a higher dose (1250 mg/m2), the observed grade 3-4 @entity137 were lower compared to some previously reported phase II and phase III @entity416 studies. CONCLUSIONS: @entity416 monotherapy is an effective and safe regimen for ER-positive, @entity1722 -negative @entity1 with @entity0 . Its low @entity137 profile compared to other intravenous cytotoxic agents and the ease of its oral administration make this agent a preferable option for both physicians and @entity1 .
